Neuralink's Scaling Plans and Valuations Following 21 Human Implants

Neuralink has implanted its brain chip in 21 clinical trial participants and secondary buyers have driven its valuation as high as $42 billion. The company's 2031 investor deck projects scaling to 20,000 surgeries annually across five clinics using a specialized robot to automate thread insertion. Realizing this plan depends on achieving regulatory reimbursement for the investigational device and successfully scaling automated surgical volume. Open article →